Loading
Genotyping 615 patients showed that about one in ten cannot make CA 19-9, that their outlook is as poor as patients with very high readings, and that a value of 7 or below is a practical way to spot them without a genetic test.
Germline whole-exome sequencing in a multicentre cohort of 615 patients with pancreatic ductal adenocarcinoma determined FUT2 and FUT3 genotypes. Receiver operating characteristic analysis identified the optimal CA 19-9 cut-off for FUT3-null status and maximally selected rank statistics derived cut-offs stratifying overall survival in a training set (307) tested in a validation set (308). FUT3-null patients had similar demographics but a much lower median baseline CA 19-9 (2.4 against 496 U/mL) and a median overall survival of 13.5 months, comparable with FUT3-intact patients above 200 U/mL (12.9 months). A cut-off of 7 U/mL identified FUT3-null status with positive predictive value 95.1% and accuracy 87.9%. Using 7 and 200 U/mL without genotyping gave four prognostic groups: above 7 to 37 (23.2 months), above 37 to 200 (22 months), above 200 (12.8 months) and 7 or below, likely FUT3-null (13.5 months).
A very low CA 19-9 is not reassurance: it marks the non-producer group whose outlook matches the highest-marker group, and it gives clinics a rule they can apply without genotyping.
Shares CA 19-9, Pancreatic ductal adenocarcinoma.
Shares CA 19-9, Pancreatic ductal adenocarcinoma.
Shares CA 19-9, Pancreatic ductal adenocarcinoma.
Shares Clinical Cancer Research, Pancreatic ductal adenocarcinoma.
Shares Clinical Cancer Research, Pancreatic ductal adenocarcinoma.
Shares CA 19-9, Pancreatic ductal adenocarcinoma.
Shares Founder mutation (BRCA1 185delAG and 5382insC, BRCA2 6174delT), Germline (hereditary) testing.
Shares Clinical Cancer Research, Pancreatic ductal adenocarcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/